XHKG
8049
Market cap172mUSD
Oct 09, Last price
2.42HKD
1D
0.00%
1Q
-1.63%
Jan 2017
49.38%
IPO
76.64%
Name
Jilin Province Huinan Changlong Bio-pharmacy Co Ltd
Chart & performance
P/E
5.80
P/S
1.28
EPS
0.36
Div yield, %
11.28%
Shrs. gr., 5y
—
Rev. gr., 5y
7.70%
Revenues
902m
+2.35%
Net income
199m
+7.94%
CFO
313m
+42.61%
Dividend
Jun 22, 20260.2873 HKD/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Jilin Province Huinan Changlong Bio-pharmacy Company Limited focuses on the manufacturing and sale of traditional Chinese medicines and various pharmaceutical products within the People's Republic of China. The company's extensive product portfolio includes a wide range of dosage forms such as tablets, capsules, and pills, as well as specialized items like Chinese medicine pretreatment and extraction products. They also provide various injectable solutions, including powders for injection, lyophilized powders for injection, and small volume liquid injections, along with active pharmaceutical ingredients (APIs) and granules. These products are primarily sold under the "Changlong" and "Qing Tong" brand names. Established in 1989, and headquartered in Kowloon, Hong Kong, the company was previously known as Jilin Province Huinan Biochemical Pharmaceutical Company Limited.
Key people
Bao Gang Zhao
Chief Finance Officer, Executive Director · since 2007
Hong Zhang
Executive Chairman of the Board, CEO, Compliance Officer, General Manager, Secretary - Party Committee · since 2010
Guo Wen Wu
Chief Engineer, Executive Director · since 2008
Xiang Fu Xu
Executive Director · since 2018
Xiao Guang Zhang
Executive Director, Deputy General Manager · since 1990
Yi Jun Zhang
Executive Director · since 2018
Ze Shu Yang
Chief Quality Officer, Chief Pharmacist and Senior Engineer
Sai Cheong Mok
Company Secretary · since 2008
Jun Gui Bai
Non-Executive Independent Director · since 2021
Qi Pin Gao
Non-Executive Independent Director · since 2018
Jie Tan
Non-Executive Independent Director
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||